Business
Earth Science Tech Inc. and Cannabis Therapeutics Inc. to hold High-Level R&D Strategy Session in Laval, Qc and announces Dr. Moutih Rafei, PhD, as a new member of the Advisory Board
Earth Science Tech Inc. and Cannabis Therapeutics Inc. to hold High-Level R&D Strategy Session in Laval, Qc and announces Dr. Moutih Rafei, PhD, as a new member of the Advisory Board.
About this update from Earth Science Tech, Inc.
[{"type":"text","content":"\n\n Hollywood, Feb. 28, 2017 (GLOBE NEWSWIRE) -- Earth Science Tech, Inc. (OTC PINK: ETST) (\"ETST\" or \"the Company\"), an innovative biotech company focused on cannabis (industrial hemp) and cannabinoid research and development, nutraceuticals, pharmaceuticals, and medical devices, and its subsidiary Cannabis Therapeutics Inc. are proud to announce that Dr. Moutih Rafei, PhD, has joined the company’s Advisory Board and that three out of the five distinguished scientists and doctors who were recently nominated to the companies’ Advisory Board will meet on Tuesday, February 28th at Le Centre Québecois d’Innovation en Biotechnologie (CQIB) in Laval, Québec, (http://www.cqib.org). \n There will be a press availability and photo op. Dr. Chandra Panchal, Dr. Domenico Fuoco, and Dr. Moutih Rafei will meet at the biotech business incubator to review and discuss ETST’s ongoing R&D projects and chart the direction of the company’s research and development initiative for near future. Missing from the gathering will be Dr. Laurent Azoulay and Dr. Calvin Higgins, M.D. who cannot leave their current work at this time. Also in attendance will be Dr. Michel Aubé, PhD, CEO and Chief Scientific Officer of ETST and Cannabis Therapeutics, Inc. At this meeting, the company will also formally launch its R&D partnership with Smart Medicine, Inc. who will provide laboratory and technical services to ETST in their facility at CQIB. ESTS R&D is focused on the development and manufacturing of nutraceutical products, generic drugs, and cannabiniod-based medicine. The company’s goal is to market its new generic drug formulations and to find new applications for those generic drugs. The development of new improved formulations of existing generic drugs will aid in the discovery of treatment for diseases that are not currently treated with those generic drugs. It is commonly known in the pharmacology community that most drugs act on biological targets that differ from those they were designed to treat. Drug repurposing is the name given to the process of finding new uses for existing drugs. Drug repurposing can be a very quick and economical way to bring a new, profitable drug to market. This is an important step for ETST. Existing drugs have been identified as potential ligands for ...